In fact, RGMB-AS1 was most frequently altered in this cancer type (Figure S1), and SPOP was altered in 12% of samples in the PRAD TCGA cohort (Figure S3F), though according to some publications [66], SPOP could be altered in up to 15% of prostate tumors. This evidence concerns the gene SPOP and cancer.